Track Ventyx Biosciences Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Ventyx Biosciences Inc. Common Stock VTYX · Stock Open Ventyx Biosciences Inc. Common Stock in new tab

14.00 USD
EPS
-1.49
P/B
5.22
ROE
-45.35
Beta
1.27
Target Price
13.00 USD
Loading chart...
Key Metrics
EPS-1.49
Book Value2.68
Price to Book5.22
Debt/Equity5.24
% Insiders4.218%
Estimates
Forward P/E-8.94
Forward EPS-1.57
Target Mean Price13.00

DCF valuation

Model fair value for Ventyx Biosciences Inc. Common Stock (VTYX)
Result
Sign in to run the valuation for VTYX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 13.00 USD (low 9.00, high 14.00)
Low 9.00
Mean 13.00
High 14.00
Price 14.00
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Ventyx Biosciences Inc. Common Stock Logo Ventyx Biosciences Inc. Common Stock Analysis (VTYX)

United States Health Care Official Website Stock

Is Ventyx Biosciences Inc. Common Stock a good investment? Ventyx Biosciences Inc. Common Stock (VTYX) is currently trading at 14.00 USD. Market analysts have a consensus price target of 13.00 USD. This suggests the asset is currently trading above analyst expectations.

Investor FAQ

Does Ventyx Biosciences Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Ventyx Biosciences Inc. Common Stock?

Ventyx Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.

Exchange Ticker
NMS (United States) VTYX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion